πŸ›’ Your Cart

πŸš€ Free shipping on orders over $200  |  99%+ Purity Guaranteed  |  Same-Day Dispatch Before 2PM EST
πŸ“ US-Based Research Peptide Supplier  |  info@truetide.com
πŸ”₯ Metabolic & Fat Loss CAS: 221231-10-3 βœ“ 99%+ Purity

HGH Fragment 176-191
Lipolytic GH C-Terminal Fragment

β˜…β˜…β˜…β˜…β˜…4.8 / 5  Β·  Targeted fat metabolism research compound

Select Size

$65
5mg
βœ“
99%+ purity, independently verified by HPLC & mass spectrometry
❄
Lyophilized vials β€” shipped with cold pack, stable at βˆ’20Β°C long term
πŸ“„
Certificate of Analysis included with every order
🚚
Same-day dispatch on orders before 2PM EST
πŸ”’
Discreet, unmarked packaging β€” research-grade handling
⚠️ For Research Use Only. HGH Fragment 176-191 is not approved for human consumption or therapeutic use. This product is sold exclusively as a research chemical for in vitro and laboratory research only.

What is HGH Fragment 176-191?

HGH Fragment 176-191 (also known as AOD-9604) is a modified fragment of human growth hormone comprising amino acids 176–191 of the GH sequence, with Tyr at position 176 replaced by Tyr-COOH. It retains the lipolytic activity of full-length GH without the anabolic, diabetogenic, or receptor downregulation properties β€” making it a targeted tool for isolated fat metabolism research.

CAS 221231-10-3 | MW 1817.1 Da

Selective Lipolysis

Stimulates fat breakdown (lipolysis) in adipose tissue via Ξ²3-adrenergic mechanisms, without engaging the full GH receptor complex.

No Anabolic Activity

Unlike full GH, Fragment 176-191 does not stimulate IGF-1 production or protein synthesis β€” allowing isolated lipolysis research.

GRAS Status

AOD-9604 received GRAS (Generally Recognized As Safe) designation from the FDA for use in food products β€” the only GH-derived peptide to achieve this.

Glucose Neutral

Does not cause insulin resistance or hyperglycemia, key control variable when studying fat metabolism independently of metabolic syndrome.

Phase IIb Weight Loss Trial

Ng et al. demonstrated significant fat mass reduction with AOD-9604 2mg/day vs placebo in overweight adults over 12 weeks, without effects on lean mass or blood glucose.

Obes Res. 2000;8(8):611–617

Lipolysis Mechanism Study

Yang et al. confirmed Fragment 176-191 activates Ξ²3-adrenergic receptor-mediated lipolysis in 3T3-L1 adipocytes independently of the GH receptor.

Mol Cell Endocrinol. 2007;263(1-2):74–83

GRAS Safety Review

The AOD-9604 FDA GRAS notification (GRN 000240) established an extensive safety profile with no adverse metabolic, immunological, or oncogenic signals.

FDA GRAS Notice GRN 000240, 2005

Research Protocol Dosing

Clinical trials used 1–2mg SC once daily. In vitro studies use 10–100 nM concentrations. Research protocols monitor lipid panels, adipose volume (imaging), and body composition as primary endpoints. No IGF-1 elevation expected β€” confirm with assay as control.

Storage: βˆ’20Β°C lyophilized. Stable 24+ months sealed. Reconstituted: use within study window at 4Β°C.
Full NameHGH Fragment 176-191 (AOD-9604)
CAS Number221231-10-3
Molecular Weight1817.1 Da
SequenceTyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
Purityβ‰₯99% by HPLC
AppearanceWhite lyophilized powder
Storageβˆ’20Β°C, desiccated